A phase 1b/II study of cancer stemness inhibitor napabucasin in combination with gemcitabine (gem) & nab-paclitaxel (nabptx) in metastatic pancreatic adenocarcinoma (mpdac) patients (pts)

被引：0
|
作者：
Bekaii-Saab, T. [1 ]
Starodub, A. [2 ,3 ]
El-Rayes, B. [4 ]
O'Neil, B. [5 ]
Shahda, S. [5 ]
Ciombor, K. [6 ]
Noonan, A. [6 ]
Hanna, W. [7 ]
Sehdev, A. [5 ]
Shaib, W. [4 ]
Mikhail, S. [6 ]
Neki, A. [6 ]
Oh, C. [8 ]
Li, Y. Z. [8 ]
Li, W. [8 ]
Borodyansky, L. [8 ]
Li, C. J. [8 ]
机构：
[1] Mayo Clin, Ctr Canc, Scottsdale, AZ USA
[2] IU Hlth Goshen Ctr Canc Care, Goshen, IN USA
[3] Parkview Hlth, Ft Wayne, IN USA
[4] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[5] IU Hlth Univ Hosp, Indianapolis, IN USA
[6] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA
[7] Univ Tennessee, Med Ctr, Knoxville, TN USA
[8] Boston Biomed Inc, Cambridge, MA USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA - 002
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer
    Perez, Kimberly
    Chiarella, Anna M.
    Cleary, James M.
    Horick, Nora
    Weekes, Colin
    Abrams, Thomas
    Blaszkowsky, Lawrence
    Enzinger, Peter
    Giannakis, Marios
    Goyal, Lipika
    Meyerhardt, Jeffrey A.
    Rubinson, Douglas
    Yurgelun, Matthew B.
    Goessling, Wolfram
    Giantonio, Bruce J.
    Brais, Lauren
    Germon, Victoria
    Stonely, Danielle
    Raghavan, Srivatsan
    Bakir, Basil
    Das, Koushik
    Pitarresi, Jason R.
    Aguirre, Andrew J.
    Needle, Michael
    Rustgi, Anil K.
    Wolpin, Brian M.
    ONCOLOGIST, 2023, 28 (05): : 425 - 432
  • [42] Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial
    Bekaii-Saab, Tanios
    Okusaka, Takuji
    Goldstein, David
    Oh, Do-Youn
    Ueno, Makoto
    Ioka, Tatsuya
    Fang, Weijia
    Anderson, Eric C.
    Noel, Marcus S.
    Reni, Michele
    Choi, Hye Jin
    Goldberg, Jonathan S.
    Oh, Sang Cheul
    Li, Chung-Pin
    Tabernero, Josep
    Li, Jian
    Foos, Emma
    Oh, Cindy
    Van Cutsem, Eric
    ECLINICALMEDICINE, 2023, 58
  • [43] A phase 1b/2 trial of SHR-1701 in combination with gemcitabine and nab-paclitaxel in patients with untreated locally advanced or metastatic pancreatic cancer.
    Zhou, Jun
    Yu, Xianjun
    Li, Zhihua
    Zhou, Yuhong
    Li, Jialin
    Xue, Ran
    Xia, Ye
    Han, Hongxia
    Wu, Yiwen
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16264 - E16264
  • [44] A phase 1b study of the anti-cancer stem cell agent demcizumab (DEM) and gemcitabine (GEM) plus /- nab-paclitaxel in patients with pancreatic cancer.
    Hidalgo, Manuel
    Cooray, Prasad
    Carrato, Alfredo
    Jameson, Michael B.
    Parnis, Francis
    Jeffery, Mark
    Grimison, Peter S.
    Stagg, Robert J.
    Holmgren, Eric
    Kapoun, Ann M.
    Dupont, Jakob
    Tebbutt, Niall C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [45] A phase 1b study of the anticancer stem cell agent demcizumab (DEM) and gemcitabine (GEM) with or without paclitaxel protein bound particles (nab-paclitaxel) in patients with pancreatic cancer
    Gracian, Antonio Cubillo
    Jameson, Michael B.
    Grande, Enrique
    Cooray, Prasad
    Parnis, Francis
    Grimison, Peter
    Jeffery, Mark
    Stagg, Robert J.
    Dupont, Jakob
    Tebbutt, Niall C.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [46] nab-paclitaxel (nab-P) plus nivolumab (Nivo) ± gemcitabine (Gem) in patients (pts) with advanced pancreatic cancer (PC).
    Firdaus, Irfan
    Waterhouse, David Michael
    Gutierrez, Martin
    Wainberg, Zev A.
    George, Ben
    Kelly, Karen
    Bekaii-Saab, Tanios S.
    Carrizosa, Daniel R.
    Soliman, Hatem Hussein
    Fraser, Cindy Duval
    Ko, Amy
    Pierce, Daniel W.
    Manax, Victoria G.
    Stergiopoulos, Sotirios G.
    Hochster, Howard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [47] A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium study
    Steven J. Cohen
    Bert H. O’Neil
    Jordan Berlin
    Patricia Ames
    Marti McKinley
    Julie Horan
    Patricia M. Catalano
    Angela Davies
    Colin D. Weekes
    Lawrence Leichman
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 693 - 701
  • [48] Phase II study of induction therapy with gemcitabine and nab-paclitaxel followed by consolidation with mFOLFIRINOX in patients with metastatic pancreatic cancer
    Ramanathan, Ramesh K.
    Lee, Peter
    Seng, John E.
    Anthony, Stephen Patrick
    Rosen, Peter J.
    Mena, Raul R.
    Picozzi, Vincent J.
    Sachdev, Jasgit C.
    Larson, Tim
    Korn, Ronald
    Jameson, Gayle S.
    Stoll, Amy C.
    Von Hoff, Daniel D.
    Leach, Joseph W.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [49] Phase II study of induction therapy with gemcitabine and nab-paclitaxel followed by consolidation with mFOLFIRINOX in patients with metastatic pancreatic cancer
    Ramanathan, Ramesh K.
    Lee, Peter
    Leach, Joseph W.
    Anthony, Stephen Patrick
    Weiss, Glen J.
    Rosen, Peter J.
    Picozzi, Vincent J.
    Sachdev, Jasgit C.
    Larson, Tim
    Korn, Ronald
    Hu, Chengcheng
    Jameson, Gayle S.
    Stoll, Amy C.
    Von Hoff, Daniel D.
    Seng, John E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [50] A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium study
    Cohen, Steven J.
    O'Neil, Bert H.
    Berlin, Jordan
    Ames, Patricia
    McKinley, Marti
    Horan, Julie
    Catalano, Patricia M.
    Davies, Angela
    Weekes, Colin D.
    Leichman, Lawrence
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (04) : 693 - 701
12345